Scarica l'app Stockscreener
23.28
0.09%
-0.0112
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$23.29
Aprire:
$23.3
Volume 24 ore:
7.84M
Relative Volume:
0.19
Capitalizzazione di mercato:
$132.21B
Reddito:
$62.46B
Utile/perdita netta:
$7.88B
Rapporto P/E:
16.87
EPS:
1.38
Flusso di cassa netto:
$11.22B
1 W Prestazione:
-6.13%
1M Prestazione:
-7.07%
6M Prestazione:
-12.25%
1 anno Prestazione:
-24.08%
Intervallo 1D:
$23.23
$23.51
Intervallo di 1 settimana:
$23.14
$24.73
Portata 52W:
$20.91
$31.32
Pfizer Inc Stock (PFE) Company Profile
Nome
Pfizer Inc
Settore
Industria
Telefono
(212) 733-2323
Indirizzo
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Confronta PFE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.25 | 135.37B | 62.46B | 7.88B | 11.22B | 1.38 |
|
LLY
Lilly Eli Co
|
759.72 | 682.35B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
165.43 | 402.82B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
193.34 | 334.40B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
114.05 | 225.78B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
78.74 | 205.28B | 63.62B | 16.41B | 17.04B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-25 | Ripresa | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-08-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Downgrade | Argus | Buy → Hold |
| 2024-02-23 | Iniziato | Guggenheim | Buy |
| 2024-01-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-10-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-17 | Reiterato | JP Morgan | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-06-29 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-07 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Downgrade | UBS | Buy → Neutral |
| 2023-01-17 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-12-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-20 | Reiterato | Cowen | Outperform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-13 | Aggiornamento | UBS | Neutral → Buy |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-05-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Aggiornamento | DZ Bank | Hold → Buy |
| 2020-12-16 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Ripresa | Goldman | Neutral |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-10-12 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-06-16 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-27 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2020-02-06 | Iniziato | Mizuho | Buy |
| 2020-01-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-07-30 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Ripresa | Morgan Stanley | Overweight |
| 2019-02-20 | Ripresa | Citigroup | Neutral |
| 2019-01-31 | Aggiornamento | Argus | Hold → Buy |
| 2019-01-31 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Downgrade | UBS | Buy → Neutral |
| 2018-12-11 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
Mostra tutto
Pfizer Inc Borsa (PFE) Ultime notizie
Moderna's Key Patent Win Overshadowed By Gloomy Outlook - Benzinga
Pfizer/BioNTech lose bid to reverse Moderna COVID vaccine patent - Seeking Alpha
Should You Buy Pfizer (PFE) Stock Before August 5? Here's What History Says - MSN
Pfizer losses appeal in Moderna patent case - breakingthenews.net
Pfizer, BioNTech lose UK appeal to overturn Moderna's COVID vaccine patent win - Reuters
UK Court of Appeal Confirms Moderna’s EP'949 Patent is Valid and Infringed by Pfizer/BioNTech - The Daily Reflector
Moderna Secures Major Patent Victory: UK Court Rules Pfizer Infringed COVID-19 Vaccine Technology - Stock Titan
Pfizer (PFE) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Trump Demands Pharma Companies Slash US Drug Prices in Letter - Bloomberg
Trump demands largest pharma companies slash US drug prices - Yahoo Finance
Purdue and Gleaners Food Bank to Open Pharmacy, Concerns Over Eli Lilly and Pfizer Relationship, IU Researchers get Top Awards, Ground Breaking for New Subsidized Housing - WFYI
Pfizer’s Promising Phase 2 Study on Advanced Breast Cancer Treatment - TipRanks
Pfizer’s New Hope: PF-08046031 Study in Advanced Melanoma and Solid Tumors - TipRanks
Pfizer’s MagnetisMM-32 Study: A New Hope for Multiple Myeloma Treatment - TipRanks
Pfizer’s Latest Study on HER2-positive Breast Cancer: A Real-World Perspective - TipRanks
Pfizer’s COVID-19 Vaccine Study: Key Insights and Market Impact - TipRanks
Pfizer’s Elranatamab Study: Continued Access for Multiple Myeloma Patients - TipRanks
Pfizer’s Phase 3 Study on Elranatamab vs. Lenalidomide: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks
Pfizer and Genmab’s Tivdak Study: Assessing Ocular Safety in Cervical Cancer Treatment - TipRanks
Pfizer’s TALZENNA Study: A Potential Game-Changer in Breast Cancer Treatment - TipRanks
Pfizer’s Sisunatovir Study: A Promising Step in RSV Treatment - TipRanks
Pfizer’s Elranatamab Study: A Real-World Insight into Multiple Myeloma Treatment - TipRanks
Stay Ahead of the Game With Pfizer (PFE) Q2 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
Pfizer: Lack Of Enthusiasm Shouldn't Surprise You - Seeking Alpha
Where Will Pfizer (PFE) Be in 5 Years? - AOL.com
Bank of America Securities Maintains a Hold on Pfizer (PFE) - Insider Monkey
Pfizer Shares Plunge 2.02% Amid Vaccine Advances and Cancer Deal, Ranked 118th in $860M Trading Volume - AInvest
Pfizer’s (PFE) Breakthrough Medicines Power its Dividend Stability - Insider Monkey
Pfizer’s TALZENNA Study: A New Hope for Prostate Cancer Treatment? - TipRanks
Pfizer’s Gene Therapy Study for Duchenne Muscular Dystrophy: A Market Game-Changer? - TipRanks
Pfizer’s Phase 3 Study on Avelumab and Axitinib in Renal Cancer: A Market Game-Changer? - TipRanks
Pfizer’s New Study on Abrocitinib: A Potential Game-Changer for Pediatric Eczema - TipRanks
Pfizer’s Latest Clinical Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Middle East and Asia Pacific Biotechnology Market Is Booming So - openPR.com
Time to Go Short on Pfizer (PFE)? - Insider Monkey
Pfizer plans to continue work in Russia in years to come - The Pharma Letter
Australia Anti-Venom Market Analysis Report 2025-2033 - GlobeNewswire
Corneal Ulcer Treatment Market Driven by Innovation from Dr. Reddy’s to Pfizer, Set for Significant Growth - FMIBlog
Pfizer’s Phase 3 Study on Elranatamab: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks
Pfizer Stock Is a Value Play Ahead of EarningsInvestors Can Short PFE Puts for Income - Yahoo Finance
Pfizer’s Promising Study on Disitamab Vedotin for Advanced Breast Cancer - TipRanks
Pfizer’s New Study on Elranatamab: A Potential Game-Changer in Multiple Myeloma Treatment? - TipRanks
Bristol-Myers Squibb and Pfizer’s Promising Study in Multiple Myeloma Treatment - TipRanks
Pfizer’s Elranatamab Study: A Continued Hope for Multiple Myeloma Patients - TipRanks
Pfizer’s New Study on Elranatamab: A Potential Game-Changer in Multiple Myeloma Treatment - TipRanks
Is Pfizer Poised for a Strong Earnings Beat and a Strategic Turnaround in 2025? - AInvest
Candidemia Market Analysis and Forecast Report 2025-2035 Featuring Pfizer, Cidara Therapeutics, Scynexis, Merck, Basilea Pharmaceutica, Lupin Pharmaceuticals, Astellas PharmaResearchAndMarkets.com - FinancialContent
Pfizer (PFE) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Pfizer Stock: Analyst Estimates & Ratings - Yahoo Finance
Cancer Drugs Market Is Booming So Rapidly 2025-2032 -Pfizer - openPR.com
North America Clinical Trials Market Forecast and Company Analysis Report 2025-2033 Featuring ICON, Wuxi AppTec, SGS, Syneos Health, PRA Health Sciences, Pfizer, IQVIA, and Medpace - Yahoo Finance
Pfizer Inc Azioni (PFE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.18%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):